CompletedPhase 3

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

NCT03588091

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

Peking University People's Hospital

Beijing, Beijing Municipality, China

+16 additional locations

Save this trial

Peking University People's HospitalBeijing, Beijing Municipality, China
The Fifth Medical Center of Chinese PLA General HospitalBeijing, Beijing Municipality, China
Fujian Medical University Union HospitalFuzhou, Fujian, China
Sun Yet-Sen University Cancer CenterGuangzhou, Guangdong, China
Guangdong Provincial People's HospitalGuangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, Guangdong, China
The Fourth Hospital of Hebei Medical UniversityShijiazhuang, Hebei, China
The affiliated cancer hospital of Zhengzhou University & Henan Cancer HospitalZhengzhou, Henan, China
Huai'an First People's HospitalHuaian, Jiangsu, China
JiangSu Province HospitalNanjing, Jiangsu, China
Shandong Cancer HospitalJinan, Shandong, China
The Affiliated Hospital Of Qingdao UniversityQingdao, Shandong, China
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China
The Second Affiliated Hospital Of Xi'an Jiaotong UniversityXian, Shanxi, China
The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, Zhejiang, China
Zhejiang Cancer HospitalHangzhou, Zhejiang, China
The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, Zhejiang, China